Does Geisinger Health Plan Cover Wegovy?
The verdict
Conditional on most plans
Geisinger Health Plan's Wegovy coverage for weight loss is employer-dependent and not publicly published in detail. Pennsylvania Medicaid dropped GLP-1 obesity coverage effective January 1, 2026, removing the weight-loss route for Geisinger Medicaid members. Commercial coverage requires the employer to have purchased the anti-obesity benefit. Medicare covers only the cardiovascular risk reduction indication with prior authorization.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Geisinger Health Plan using your member ID.
Key facts
Pennsylvania Medicaid dropped GLP-1 obesity coverage effective January 1, 2026, ending the weight-loss Wegovy pathway for Geisinger and UPMC Medicaid members in Pennsylvania.
Pennsylvania Department of Human Services, 2026 Medicaid drug coverage update
Geisinger Health Plan's Wegovy coverage detail is not publicly published at the drug level — in contrast to Highmark, which cites named anti-obesity policies (J-0184 for commercial, J-1370 for Medicare CV).
Geisinger Health Plan member resources; Highmark coverage policies J-0184 and J-1370
Wegovy is FDA-approved for chronic weight management (BMI 30+, or 27+ with a weight-related comorbidity) and for cardiovascular risk reduction in adults with established CVD — it is a weight-loss and CV drug, not a diabetes drug.
FDA, Wegovy (semaglutide) prescribing information
Medicare vs. commercial coverage
Whether Geisinger Health Plan covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by federal statute. For Geisinger Medicare members with established cardiovascular disease who are overweight or obese, the cardiovascular risk reduction indication is coverable under Part D with prior authorization. The $2,100 beneficiary OOP cap applies in 2026. The Medicare GLP-1 Bridge (launching July 1, 2026, through December 31, 2027) provides weight-loss access to Wegovy at a fixed $50 per month copay outside Part D — this does not count toward the deductible, TrOOP, or the $2,100 cap. Bridge eligibility requires provider attestation: BMI 35 or higher; or BMI 30 or higher with heart failure, uncontrolled hypertension, or CKD; or BMI 27 or higher with prediabetes, prior MI, prior stroke, or symptomatic PAD. Members already receiving a Part D-covered GLP-1 are ineligible. Medicare beneficiaries cannot use the NovoCare savings card.
Commercial / Employer
Group & marketplace plans
Geisinger Health Plan is a Pennsylvania provider-sponsored insurer serving central and northeastern Pennsylvania. For commercial and employer-sponsored members, Wegovy weight-loss coverage is employer-dependent — the employer must have purchased the anti-obesity benefit. Drug-level Wegovy coverage detail is not publicly published by Geisinger. ACA/individual plans generally exclude Wegovy for weight loss. Pennsylvania Medicaid dropped GLP-1 obesity coverage effective January 1, 2026 — Geisinger Medicaid members can no longer access Wegovy for weight loss through the state benefit, though a non-weight-loss FDA indication (such as the cardiovascular indication) remains covered. Verify commercial coverage on the Geisinger drug-lookup tool and confirm with HR whether the anti-obesity benefit is included.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349 per month (Novo Nordisk published list price for a 28-day supply)
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial cost-share where the employer opted in: not publicly published; varies by plan tier. NovoCare Wegovy Savings Offer: commercially insured Geisinger members whose plan covers Wegovy may pay as little as $25 per month (max savings $100 per 28-day supply). PA Medicaid: Wegovy for weight loss no longer covered (effective 1/1/2026). Medicare CV indication: Part D cost-share depends on tier and benefit phase; $2,100 OOP cap 2026. Medicare Bridge (weight loss, from 7/1/2026): fixed $50 per month outside Part D.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare self-pay program: approximately $199 per month for starting doses (0.25/0.5 mg, first two fills through December 31, 2026), then approximately $349 per month for standard doses. Not available to Medicare or Medicaid beneficiaries. From January 1, 2027, Novo Nordisk has announced a list-price reduction to approximately $675 per month; the IRA-negotiated Maximum Fair Price of $274 per 30-day supply also takes effect January 1, 2027.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Actual cost-share varies by plan tier and pharmacy. Confirm with Geisinger Health Plan member services or the plan drug-lookup tool.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Run Wegovy through the Geisinger drug-lookup tool
Visit the Geisinger Health Plan member portal and search for Wegovy (semaglutide 2.4 mg) under your specific plan. Confirm coverage status, tier (if any), and prior-authorization requirements for your plan.
- 2
Confirm with HR whether the anti-obesity benefit is included
Because weight-loss coverage is employer-dependent, ask your HR department directly whether anti-obesity or weight-loss drugs are included in your plan's benefit design. If the benefit is excluded at the employer level, prior-authorization paperwork will not change that outcome.
- 3
Ask your prescriber about the CV indication or Bridge eligibility
If you have established cardiovascular disease and are overweight or obese, ask your provider whether the cardiovascular risk reduction indication applies. Medicare members should also ask about the GLP-1 Bridge (launching July 1, 2026, $50/month outside Part D). PA Medicaid members should note that weight-loss GLP-1 coverage is no longer available through PA Medicaid as of January 1, 2026.
Options if Geisinger Health Plan won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Cardiovascular indication (Medicare Part D or commercial)
Wegovy is FDA-approved for cardiovascular risk reduction in adults with established CVD who are overweight or obese. This indication may be coverable under Medicare Part D or certain Geisinger commercial plans with prior authorization, separate from the weight-loss benefit.
Medicare GLP-1 Bridge
Launching July 1, 2026, the Bridge provides eligible Medicare beneficiaries weight-loss access to Wegovy at $50 per month through December 31, 2027, outside Part D. Eligibility criteria apply; members already on a Part D-covered GLP-1 are ineligible.
NovoCare self-pay program
For members without coverage, Novo Nordisk's NovoCare program offers approximately $199 per month for starting doses (first two fills through December 31, 2026), then approximately $349 per month for standard injection doses. Not available to Medicare or Medicaid beneficiaries. Verify current pricing at novocare.com.
Compounded semaglutide
Compounded semaglutide, available through licensed telehealth platforms, does not require insurance prior authorization. Starting from $49 per month. Compounded semaglutide is not the same medication as Wegovy and has not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Coverage depends on your plan type. Commercial members need the employer to have purchased the anti-obesity benefit — Geisinger does not publicly publish drug-level Wegovy detail, so verify through the drug-lookup tool and HR. Pennsylvania Medicaid members cannot access Wegovy for weight loss through PA Medicaid as of January 1, 2026 — the state dropped GLP-1 obesity coverage. Medicare covers the CV indication only. Cash and compounded options exist outside insurance.
Geisinger and UPMC are both Pennsylvania provider-sponsored health plans with not-publicly-published Wegovy coverage detail, and both serve PA Medicaid populations that lost GLP-1 obesity coverage effective January 1, 2026. The key difference is geographic footprint: Geisinger primarily serves central and northeastern Pennsylvania, while UPMC focuses on western Pennsylvania. Both require employer opt-in for commercial weight-loss coverage. Highmark, the third major PA plan, differs by having named anti-obesity policies (J-0184, J-1370) that are citable and specific.
No. Pennsylvania Medicaid dropped GLP-1 obesity coverage effective January 1, 2026. Geisinger Medicaid members can no longer access Wegovy for weight management through the PA Medicaid benefit. The cardiovascular risk reduction indication remains covered under applicable Medicaid programs for members with established CVD. Wegovy is not a diabetes drug and cannot be routed through a diabetes benefit.
Commercially insured Geisinger members whose plan covers Wegovy may use the NovoCare Wegovy Savings Offer (as little as $25 per month, max savings $100 per 28-day supply). The card is not available to Medicare or Medicaid beneficiaries. PA Medicaid members have lost weight-loss GLP-1 coverage and cannot use the card for Medicaid claims. ACA exchange and state-employee plans are not treated as government programs for this offer.
Highmark has published named anti-obesity policies — J-0184 for commercial weight-loss coverage and J-1370 for the Medicare CV indication — giving patients and providers specific, citable criteria to work from. Geisinger's drug-level Wegovy detail is not publicly published, requiring members to verify through the drug-lookup tool. Both operate in Pennsylvania and share the PA Medicaid 1/1/2026 obesity coverage drop for their Medicaid members, but Highmark's transparency level is notably higher.
Related Articles
Does Geisinger Health Plan Cover Mounjaro? 2026 Guide | Curex
Geisinger covers Mounjaro for type 2 diabetes with prior auth — not weight loss. PA Medicaid is diabetes-only after the 2025 weight-loss GLP-1 cut.
Read moreDoes Group Health Cooperative Cover Wegovy? 2026 | Curex
Group Health Cooperative covers Wegovy only where your employer opted in. Wisconsin co-op — drug-level detail not public. Verify on GHC's drug-lookup tool.
Read moreDoes Security Health Plan Cover Wegovy? 2026 | Curex
Security Health Plan (Marshfield Clinic) covers Wegovy only where your employer opted in. Not publicly published — verify on the plan's drug-lookup tool.
Read moreDoes Fallon Community Health Plan Cover Wegovy? | Curex
Fallon covers Wegovy only where your employer opted in. New England is tightening — BCBS-MA ended GLP-1 coverage in 2026. Verify your plan.
Read moreDoes Geisinger Health Plan Cover Ozempic? 2026 Guide | Curex
Geisinger covers Ozempic for T2D with PA — not weight loss. Risant/Kaiser ownership does not import Kaiser SGLT-2 step. Verify on Geisinger drug lookup.
Read moreDoes UPMC Health Plan Cover Wegovy? PA Plans 2026 | Curex
UPMC covers Wegovy for weight loss only where employers opted in. PA Medicaid dropped GLP-1 obesity coverage January 2026. Verify on UPMC drug lookup.
Read moreWhether or not Geisinger Health Plan covers Wegovy, there's a path that skips insurance
Geisinger commercial coverage depends on employer opt-in, and Pennsylvania Medicaid dropped Wegovy weight-loss coverage in 2026. For patients without a covered route, compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) is available at Curex — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Geisinger Health Plan before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.